Blocking a specific immune signal to improve kidney transplant outcomes
Selective CD28 Blockade in Renal Transplant Recipients
This study is looking at a new medication that could help kidney transplant patients by reducing the chances of their body rejecting the new kidney while still keeping the benefits of an existing treatment, making recovery easier and safer for them.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10465024 on NIH RePORTER |
What this research studies
This research investigates a new approach to improve kidney transplant success by using a novel drug that selectively blocks CD28, a protein involved in immune response. The goal is to reduce the risk of acute rejection while maintaining the benefits of a previously approved immunosuppressant, belatacept. By focusing on this targeted blockade, the research aims to enhance graft survival and minimize complications associated with traditional immunosuppressive therapies. Patients may benefit from improved transplant outcomes and reduced side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have received a kidney transplant or are awaiting a kidney transplant.
Not a fit: Patients who are not undergoing kidney transplantation or those with contraindications to immunosuppressive therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better kidney transplant outcomes and lower rates of graft rejection for patients.
How similar studies have performed: Previous research has shown promising results with similar targeted immunosuppressive approaches, indicating potential for success in this novel method.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Larsen, Christian P. — Emory University
- Study coordinator: Larsen, Christian P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.